Statins

DRUG13 trials

Sponsors

Organon and Co, Rockefeller University, National Institute of Cardiology, Warsaw, Poland, Hospital Universitario Getafe, Pronova BioPharma

Conditions

Acute Ischemic StrokeBreast Cancer FemaleCardiovascular DiseasesDyslipidemiaHeart DiseasesHeart FailureHomozygous Familial HypercholesterolemiaHypercholesterolaemia

Phase 2

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

TerminatedNCT01972178

Pronova BioPharmaDyslipidemia

Start: 2013-11-30End: 2014-08-31Updated: 2015-10-30

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

CompletedNCT02890992

SanofiHypercholesterolaemia

Start: 2016-09-15End: 2019-02-22Updated: 2019-09-06

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

CompletedNCT03933293

AkesoHomozygous Familial Hypercholesterolemia

Start: 2019-05-13End: 2021-03-15Updated: 2023-03-02

Phase 3

Statins and ARBs on Rheumatoid Activity

RecruitingNCT03770702

Sherief Abd-ElsalamRheumatoid Arthritis

Start: 2018-10-01End: 2026-12-01Target: 45Updated: 2018-12-10

Statins In Intracerbral Hemorrhage

RecruitingNCT03936361

Beth Israel Deaconess Medical CenterIntracerebral Hemorrhage

Start: 2020-06-10End: 2028-12-31Target: 1456Updated: 2025-09-19

Survival Benefits of Statins in Breast Cancer Patients

Peking Union Medical College HospitalBreast Cancer Female

Start: 2019-03-28End: 2024-06-28Target: 314Updated: 2019-08-14

Phase 4

Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)

CompletedNCT00652847

Organon and CoHypercholesterolemia

Start: 2005-05-31End: 2007-05-31Updated: 2024-08-15

Quality of Life in Patients With Statin-Associated Myopathy

TerminatedNCT00850460

Rockefeller UniversityStatin Adverse Reaction

Start: 2009-02-28End: 2013-02-28Updated: 2016-11-07

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

CompletedNCT02642159

SanofiDyslipidemia

Start: 2016-03-15End: 2017-05-15Updated: 2018-05-01

Unknown Phase

Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment

TerminatedNCT00968383

National Institute of Cardiology, Warsaw, PolandCardiovascular Diseases, Heart Diseases, Heart Failure +1

Start: 2009-09-30End: 2012-12-31Updated: 2015-05-14

Safety and Efficacy Study of Bosentan for Intermittent Claudication in Peripheral Arterial Disease

CompletedNCT01738542

Hospital Universitario GetafePeripheral Arterial Disease

Start: 2009-04-30End: 2010-11-30Updated: 2012-11-30

The effects of statins on skeletal muscle mitochondria:a pilot study?

Active, not recruitingNL-OMON42199

Integrative fysiologieskeletspier mitochondriale functie, algemene spierfunctie en fitheid the effects of statins on musle mitochondrial function the effects of statins on the aerobic energy metabolism

Start: 2015-11-11Target: 30Updated: 2024-02-28

Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Xuanwu Hospital, BeijingAcute Ischemic Stroke

Start: 2023-12-01End: 2024-12-01Target: 80Updated: 2023-11-18

Related Papers

SATURN MRI: study protocol for the statin use in intracerebral hemorrhage patients MRI ancillary study

Trials2025-08-30

PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.

2020-03-2836 citations

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

Cardiovascular Diabetology2020-02-0831 citations

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.

2019-11-0926 citations

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

2018-03-2364 citations

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

2017-05-2517 citations